
Akari Therapeutics fell 66.1% from $19.20 to $6.51, behind the S&P 500's +11.2%. Its worst day was May 12 (−40.6%), and its low came May 12 at $3.06.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $0.00 beat the $-2.80 estimate on $0.00 revenue.
+6.4% · S&P 500 +2.9%
Akari Therapeutics closed at its lowest level of the year, 84.1% below where the year started.
Story events cover the past 12 months · Times ET
−40.6%, the year's worst day · S&P 500 −0.2%
EPS of $0.00 beat the $-2.80 estimate on $0.00 revenue.
0.0% · S&P 500 +1.0%
Akari Therapeutics closed at its highest level of the year, 14.8% above where the year started.
+38.5% · S&P 500 +0.6%
EPS of $0.00 beat the $-1.04 estimate on $0.00 revenue.
+7.6% · S&P 500 −0.2%
EPS of $0.00 beat the $-2.38 estimate on $0.00 revenue.
+4.5% · S&P 500 −0.4%
Where it ended: a close of $6.51 on Nov 16, 2026.
Nothing in the past 12 months.
All AKTX dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for AKTX and SPY from Benzinga historical bars. Not investment advice.